Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Moves to Delist Response Genetics

NEW YORK (GenomeWeb) – Response Genetics may be delisted from the Nasdaq Capital Market after failing to comply with two requirements to remain listed, the firm disclosed in a document filed with the US Securities and Exchange Commission on Dec. 24.

The Los Angeles-based molecular diagnostics firm said in a Form 8-K that it received a delisting determination letter from Nasdaq on Dec. 19 because it was not in compliance with the minimum bid price of $1.00 requirement for continued listing. The letter also stated that the firm was not eligible for an extension to regain compliance because it did not meet the minimum $2.5 million in stockholders’ equity needed for continued listing.

The firm said it intended to appeal the delisting determination by the Dec. 26 deadline, which would stay a suspension of its securities until a hearing process is completed.

On Dec. 11, Nasdaq sent Response Genetics a letter stating that it did not meet a listing requirement calling for a minimum of $2.5 million stockholders' equity. 

The firm said it expects its common stock to be traded on the Over-the-Counter Bulletin Board if it ceases to be listed on the Nasdaq Capital Market.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.